Popular Articles

Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial Of Picoplatin In Metastatic Colorectal Cancer
Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced updated clinical data from its randomized, controlled Phase 2 trial of picoplatin in patients with metastatic colorectal cancer (CRC). The new data demonstrated that picoplatin, given once every four weeks in combination with 5-fluorouracil and leucovorin in the FOLPI regimen, and oxaliplatin, given in combination with 5-fluorouracil and leucovorin in the modified FOLFOX-6 regimen, have similar anti-tumor activity in the treatment of first-line metastatic CRC, as assessed by progression-free survival (PFS) and disease control measured by tumor response rate. New data derived by three independent assessments of neurotoxicity indicated a statistically significant reduction in neurotoxicities with the use of picoplatin in FOLPI compared with oxaliplatin in FOLFOX (pPhase 2 CRC Trial Design and Updated Results
generic viagra online
What Is Heart Failure? What Causes Heart Failure?
Even though it may sound like it, heart failure does not necessarily mean that the heart has failed. Heart failure is a serious condition in which the heart is not pumping blood around the body efficiently. The patient"s left side, right side, or even both sides of the body can be affected. Symptoms will depend on which side is affected and how severe the heart failure is - symptoms can be severe.
News of the day
CBO: Health Reform Bills Bend Cost Curve In Wrong Direction
"Congress"s chief budget analyst delivered a devastating assessment yesterday of the health-care proposals drafted by congressional Democrats, fueling an insurrection among fiscal conservatives in the House and pushing negotiators in the Senate to redouble efforts to draw up a new plan that more effectively restrains federal spending," the Washington Post reports.
Sexual Health

Heatwave Plan Updated With Advice For Those With Respiratory Problems, England

The Heatwave Plan has been updated to advise those suffering breathing problems that although ozone levels increase in hot weather, they drop in the evening. People with respiratory problems should stay inside during the hottest part of the day and windows should be kept shaded and closed when the temperature is hotter outside than inside. The benefits of insulating against both heat and cold are outlined, with information on grants that are available from government. Providing cavity insulation in houses helps keep the heat out during summer, as well as keeping homes warm and reducing fuel costs and carbon emissions during colder weather. More information on the Health Housing and Safety Rating System is also provided in the Plan. This encourages primary care trusts and local authorities to work more closely to target, assess and reduce the risk of vulnerable people living in the community who are living in homes that are too hot for their health. Yvonne Doyle, Regional Director of Public Health (South East Coast) said: "The heatwave plan urges carers to identify those most at risk before the hot weather begins. Once level 2, "Alert and Readiness" has been triggered, those running care homes are urged to take extra care. They should monitor indoor temperatures four times a day, prepare cool areas, ensure there are enough staff to keep residents cool, identify those at greatest risk and make sure everyone has access to cold water and ice." Wayne Elliott, head of health forecasting at the Met Office said: "The Department of Health"s Heatwave Plan is a vital part of the country"s preparation for coping with extreme temperatures. The prolonged spells of hot weather that can happen each summer, particularly in our towns and cities, are a very real concern for vulnerable groups." The alert levels are now described from Level 1-4, but are also given colours that mirror the traffic light system. Link to the Heatwave Plan Department of Health, UK


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):